Familiar Bay Area leaders including Theranos’ Elizabeth Holmes, Verily’s Andrew Conrad, and Anne Wojcicki of 23andMe, have made FierceBiotech‘s 2016 “Most Influential in Biopharma Today” list – but others may surprise you. Excerpt from the intro of their special feature:
“We’ve put together a list of the people in and around biopharma who are poised to play major roles in the industry’s evolution. Some are recent hires hoping to rescue moribund giants, while others are long-tenured veterans trying to steer their firms into brighter futures.
Each is facing a make-or-break 2016 with wide implications for the drug business as a whole.
Can Ian Read’s Pfizer deliver on its big goals after a record-breaking merger? How will John Milligan keep Gilead Sciences rolling when its blockbusters plateau? Can Anne Wojcicki complete 23andMe’s turnaround? And will Martin Shkreli stay out of prison long enough to start another company?
As is the case every year, “most influential” does not necessarily mean “most innovative,” “most successful” or even “most admirable.” Failures often change the landscape more than successes, as a few members of this list can attest. And kicking down doors can be more effective than building consensus.
Here are the individuals shaping the future of biopharma in 2016, whether through breakthrough science, back-room dealmaking or outright bullying.”